Enweida (envafolimab)

Combination of chidamide and envafolimab showed efficacy signals in certain NSCLC patients. But further identification of beneficial population is necessary for precision treatment.

P2, N=126, Recruiting, 3D Medicines (Sichuan) Co., Ltd. | N=200 --> 126 | Trial completion date: Apr 2024 --> Apr 2028 | Trial primary completion date: Apr 2024 --> Aug 2027

P2, N=207, Active, not recruiting, Ascletis Pharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Jun 2023 --> Aug 2024

P2, N=198, Recruiting, Sun Yat-sen University | Active, not recruiting --> Recruiting

P2, N=60, Recruiting, Beijing Hospital

P2, N=86, Terminated, Jiangsu Simcere Pharmaceutical Co., Ltd. | Trial completion date: Dec 2023 --> Jul 2023 | Recruiting --> Terminated; The study was terminated due to the sponsor's research and development strategy adjustment.

P2, N=16, Recruiting, Nanjing First Hospital, Nanjing Medical University

P2, N=200, Recruiting, 3D Medicines (Sichuan) Co., Ltd. | Trial primary completion date: Dec 2023 --> Jun 2024

P3, N=390, Recruiting, 3D Medicines (Sichuan) Co., Ltd. | Not yet recruiting --> Recruiting

Moreover, after antitumor treatment, [Zr]Zr-DFO-KN035 enabled observational imaging for therapeutic efficacy evaluation, which can help predict patient prognosis. [Zr]Zr-DFO-KN035 can be used for the diagnosis and therapy monitoring of PD-L1-positive tumors and provide noninvasive and comprehensive observations for tumor diagnostic imaging, prognosis prediction, and efficacy evaluation.

P2, N=38, Recruiting, Liangjun Zhu M.M. | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2023 --> Dec 2024

P1/2, N=145, Suspended, LaNova Medicines Limited

P2, N=32, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine

P2, N=48, Not yet recruiting, Sun Yat-sen University

No abstract available

P1/2, N=145, Suspended, LaNova Medicines Limited | Recruiting --> Suspended

P2, N=198, Active, not recruiting, Sun Yat-sen University | Not yet recruiting --> Active, not recruiting

P3, N=390, Not yet recruiting, 3D Medicines (Sichuan) Co., Ltd.

P2, N=30, Not yet recruiting, Chongqing University Cancer Hospital

P2, N=46, Not yet recruiting, Fudan University

P2, N=30, Enrolling by invitation, Fudan University

This prospective study showed that Envafolimab combined with Endostar has promising efficacy and good tolerability in advanced NSCLC with PD-L11%. This combination provided a new choice and a prospective study in furture was expected.

P2, N=100, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Aug 2030

Most of the adverse reactions were mild and the rate of 3/4 grade TEAE was 10.37% (95% CI, 6.14-14.60%). Gevokizumab was effective and safe in the treatment of patients with advanced dMMR/MSI-H solid tumors and its convenience could significantly improve patient compliance; therefore, the clinical application of envafolimab is promising.

P2, N=198, Not yet recruiting, Sun Yat-sen University

Envafolimab plus suvemcitug and docetaxel were administrated until disease progression or unacceptable toxicity...There was no grade 5 TRAE in either cohort. Conclusions This phase II clinical trial demonstrated antitumor activity and manageable safety profile of immunotherapy plus anti-angiogenic agent and chemotherapy in pts with NSCLC, who had failed at least one line of therapy.

Research Sponsor: Shanghai Xianxiang Medical Technology Co., Ltd. and 3D Medicines Inc.

Eligible pts had received at least one prior line of treatment for MSS/pMMR mCRC and were treated with envafolimab plus suvemcitug and FOLFIRI (Irinotecan, Leucovorin, and 5-Fluorouracil)...Conclusions To the best of our knowledge, this is the first study demonstrated promising antitumor activity and a manageable safety profile of immunotherapy plus anti-angiogenic agent and chemotherapy in pts with MSS/ pMMR mCRC who had failed at least one line of therapy. The results support further evaluation of the therapy in a larger population.

Background Gemcitabine plus cisplatin (GP) prior to concurrent chemoradiotherapy (CCRT) has favorable survival outcomes with acceptable toxicity in patients with locoregionally advanced nasopharyngeal carcinoma (LANPC)...Conclusions Envafolimab plus chemoradiotherapy was effective and safety in the treatment of LANPC. Further follow-up is needed to confirm the long-term efficacy.

P2, N=200, Recruiting, 3D Medicines (Sichuan) Co., Ltd. | Trial primary completion date: Apr 2023 --> Apr 2024

P2, N=20, Not yet recruiting, Shanghai 6th People's Hospital

P2, N=100, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

P2, N=40, Recruiting, The First People's Hospital of Lianyungang | Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Jan 2023 --> May 2024

P2, N=132, Not yet recruiting, Fudan University

P2, N=80, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

P2, N=39, Completed, Zhejiang University | Recruiting --> Completed | Trial completion date: Jan 2024 --> Jun 2023

P=N/A, N=30, Not yet recruiting, Peking University Third Hospital

P2, N=30, Recruiting, Sir Run Run Shaw Hospital

P2, N=32, Active, not recruiting, Sir Run Run Shaw Hospital | Recruiting --> Active, not recruiting

P3, N=108, Recruiting, Sir Run Run Shaw Hospital | Not yet recruiting --> Recruiting

P2, N=33, Recruiting, Jiangxi Provincial Cancer Hospital

P1/2, N=145, Recruiting, LaNova Medicines Limited | Not yet recruiting --> Recruiting